Delays in reaching clinical proof-of-concept can dramatically increase biotech cash burn

The article explains how the timing of achieving clinical proof‑of‑concept (POC) directly affects a biotech company's cash consumption. While a study’s cost is important, the ongoing expenses of staff, facilities, partners and regulatory work continue each month until POC is demonstrated.

A survey of twelve founder‑led biotech firms estimated an average cash burn of about $20,000 per employee each month. That translates to roughly $200,000 for a ten‑person team and $2 million for a hundred‑person organization.

Extending development by six to twelve months could therefore add between $1.2 million and $24 million in cash‑burn exposure, depending on company size. These figures illustrate how even modest delays can erode runway.

The author cautions that the numbers are hypothetical and based on a small sample, but they highlight the financial incentive for companies to accelerate POC milestones.